MedTrace Logo

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

NCT03747419 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-10-31

Study results available
· View outcomes & findings →

Summary

This research study is studying the effects of adding a certain type of immunotherapy to standard bladder-directed radiation as a treatment for muscle-invasive urothelial carcinoma of the bladder.

The drug in this study is: Avelumab (also known as BAVENCIO®)

Conditions

Interventions

DRUG

Avelumab

Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.

RADIATION

Radiation

Cancer treatment that uses ionizing radiation to kill cancer cells.

Sponsors & Collaborators

Principal Investigators

  • Kent Mouw, MD, PhD · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-13
Primary Completion
2025-02-24
Completion
2025-02-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03747419 on ClinicalTrials.gov